Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

Zachariah DeFilipp; Anjali S. Advani; Veronika Bachanova; Ryan D. Cassaday; Daniel J. Deangelo; Partow Kebriaei; Jacob M. Rowe; Matthew D. Seftel; Wendy Stock; Martin S. Tallman; Suzanne Fanning; Yoshihiro Inamoto; Ankit Kansagra; Laura Johnston; Arnon Nagler; Craig S. Sauter; Bipin N. Savani; Miguel Angel Perales; Paul A. Carpenter; Richard A. Larson; Daniel Weisdorf

doi:10.1016/j.bbmt.2019.08.014

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

Zachariah DeFilipp, Anjali S. Advani, Veronika Bachanova, Ryan D. Cassaday, Daniel J. Deangelo, Partow Kebriaei, Jacob M. Rowe, Matthew D. Seftel, Wendy Stock, Martin S. Tallman, Suzanne Fanning, Yoshihiro Inamoto, Ankit Kansagra, Laura Johnston, Arnon Nagler, Craig S. Sauter, Bipin N. Savani, Miguel Angel Perales, Paul A. Carpenter, Richard A. LarsonDaniel Weisdorf

Research output: Contribution to journal › Review article › peer-review

64 Scopus citations

Abstract

The role of hematopoietic cell transplantation (HCT) in adults with acute lymphoblastic leukemia (ALL) is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the recommendations. A panel of ALL experts developed consensus on the treatment recommendations based on the evidence. Allogeneic HCT offers a survival benefit in selected patients with ALL, and this review summarizes the standard indications as well as the areas of controversy. There is now greater experience with pediatric-inspired chemotherapy regimens that has transformed upfront therapy for adult ALL, resulting in higher remission rates and overall survival. This in turn has increased the equipoise around decision making for ALL in first complete remission (CR1) when there is no measurable residual disease (MRD) at the end of induction and/or consolidation. Randomized studies are needed for adults with ALL to compare allogeneic HCT in CR1 with pediatric-inspired chemotherapy alone. Indications for transplantation in the evolving landscape of MRD assessments and novel targeted and immune therapeutics remain important areas of investigation.

Original language	English (US)
Pages (from-to)	2113-2123
Number of pages	11
Journal	Biology of Blood and Marrow Transplantation
Volume	25
Issue number	11
DOIs	https://doi.org/10.1016/j.bbmt.2019.08.014
State	Published - Nov 2019

Keywords

Acute lymphoblastic leukemia
Allogeneic hematopoietic cell transplantation
Autologous stem cell transplantation
Evidence-based review
Guideline

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1016/j.bbmt.2019.08.014

Cite this

DeFilipp, Z., Advani, A. S., Bachanova, V., Cassaday, R. D., Deangelo, D. J., Kebriaei, P., Rowe, J. M., Seftel, M. D., Stock, W., Tallman, M. S., Fanning, S., Inamoto, Y., Kansagra, A., Johnston, L., Nagler, A., Sauter, C. S., Savani, B. N., Perales, M. A., Carpenter, P. A., ... Weisdorf, D. (2019). Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 25(11), 2113-2123. https://doi.org/10.1016/j.bbmt.2019.08.014

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. / DeFilipp, Zachariah; Advani, Anjali S.; Bachanova, Veronika et al.
In: Biology of Blood and Marrow Transplantation, Vol. 25, No. 11, 11.2019, p. 2113-2123.

Research output: Contribution to journal › Review article › peer-review

DeFilipp, Z, Advani, AS, Bachanova, V, Cassaday, RD, Deangelo, DJ, Kebriaei, P, Rowe, JM, Seftel, MD, Stock, W, Tallman, MS, Fanning, S, Inamoto, Y, Kansagra, A, Johnston, L, Nagler, A, Sauter, CS, Savani, BN, Perales, MA, Carpenter, PA, Larson, RA & Weisdorf, D 2019, 'Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy', Biology of Blood and Marrow Transplantation, vol. 25, no. 11, pp. 2113-2123. https://doi.org/10.1016/j.bbmt.2019.08.014

DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, Deangelo DJ, Kebriaei P et al. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation. 2019 Nov;25(11):2113-2123. doi: 10.1016/j.bbmt.2019.08.014

@article{b1dca4d6fdd744f9a5fdd6af8ba19139,

title = "Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy",

abstract = "The role of hematopoietic cell transplantation (HCT) in adults with acute lymphoblastic leukemia (ALL) is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the recommendations. A panel of ALL experts developed consensus on the treatment recommendations based on the evidence. Allogeneic HCT offers a survival benefit in selected patients with ALL, and this review summarizes the standard indications as well as the areas of controversy. There is now greater experience with pediatric-inspired chemotherapy regimens that has transformed upfront therapy for adult ALL, resulting in higher remission rates and overall survival. This in turn has increased the equipoise around decision making for ALL in first complete remission (CR1) when there is no measurable residual disease (MRD) at the end of induction and/or consolidation. Randomized studies are needed for adults with ALL to compare allogeneic HCT in CR1 with pediatric-inspired chemotherapy alone. Indications for transplantation in the evolving landscape of MRD assessments and novel targeted and immune therapeutics remain important areas of investigation.",

keywords = "Acute lymphoblastic leukemia, Allogeneic hematopoietic cell transplantation, Autologous stem cell transplantation, Evidence-based review, Guideline",

author = "Zachariah DeFilipp and Advani, {Anjali S.} and Veronika Bachanova and Cassaday, {Ryan D.} and Deangelo, {Daniel J.} and Partow Kebriaei and Rowe, {Jacob M.} and Seftel, {Matthew D.} and Wendy Stock and Tallman, {Martin S.} and Suzanne Fanning and Yoshihiro Inamoto and Ankit Kansagra and Laura Johnston and Arnon Nagler and Sauter, {Craig S.} and Savani, {Bipin N.} and Perales, {Miguel Angel} and Carpenter, {Paul A.} and Larson, {Richard A.} and Daniel Weisdorf",

note = "Publisher Copyright: {\textcopyright} 2019 American Society for Transplantation and Cellular Therapy",

year = "2019",

month = nov,

doi = "10.1016/j.bbmt.2019.08.014",

language = "English (US)",

volume = "25",

pages = "2113--2123",

journal = "Biology of Blood and Marrow Transplantation",

issn = "1083-8791",

publisher = "Elsevier Inc.",

number = "11",

}

TY - JOUR

T1 - Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia

T2 - Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

AU - DeFilipp, Zachariah

AU - Advani, Anjali S.

AU - Bachanova, Veronika

AU - Cassaday, Ryan D.

AU - Deangelo, Daniel J.

AU - Kebriaei, Partow

AU - Rowe, Jacob M.

AU - Seftel, Matthew D.

AU - Stock, Wendy

AU - Tallman, Martin S.

AU - Fanning, Suzanne

AU - Inamoto, Yoshihiro

AU - Kansagra, Ankit

AU - Johnston, Laura

AU - Nagler, Arnon

AU - Sauter, Craig S.

AU - Savani, Bipin N.

AU - Perales, Miguel Angel

AU - Carpenter, Paul A.

AU - Larson, Richard A.

AU - Weisdorf, Daniel

PY - 2019/11

Y1 - 2019/11

N2 - The role of hematopoietic cell transplantation (HCT) in adults with acute lymphoblastic leukemia (ALL) is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the recommendations. A panel of ALL experts developed consensus on the treatment recommendations based on the evidence. Allogeneic HCT offers a survival benefit in selected patients with ALL, and this review summarizes the standard indications as well as the areas of controversy. There is now greater experience with pediatric-inspired chemotherapy regimens that has transformed upfront therapy for adult ALL, resulting in higher remission rates and overall survival. This in turn has increased the equipoise around decision making for ALL in first complete remission (CR1) when there is no measurable residual disease (MRD) at the end of induction and/or consolidation. Randomized studies are needed for adults with ALL to compare allogeneic HCT in CR1 with pediatric-inspired chemotherapy alone. Indications for transplantation in the evolving landscape of MRD assessments and novel targeted and immune therapeutics remain important areas of investigation.

AB - The role of hematopoietic cell transplantation (HCT) in adults with acute lymphoblastic leukemia (ALL) is reviewed and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the recommendations. A panel of ALL experts developed consensus on the treatment recommendations based on the evidence. Allogeneic HCT offers a survival benefit in selected patients with ALL, and this review summarizes the standard indications as well as the areas of controversy. There is now greater experience with pediatric-inspired chemotherapy regimens that has transformed upfront therapy for adult ALL, resulting in higher remission rates and overall survival. This in turn has increased the equipoise around decision making for ALL in first complete remission (CR1) when there is no measurable residual disease (MRD) at the end of induction and/or consolidation. Randomized studies are needed for adults with ALL to compare allogeneic HCT in CR1 with pediatric-inspired chemotherapy alone. Indications for transplantation in the evolving landscape of MRD assessments and novel targeted and immune therapeutics remain important areas of investigation.

KW - Acute lymphoblastic leukemia

KW - Allogeneic hematopoietic cell transplantation

KW - Autologous stem cell transplantation

KW - Evidence-based review

KW - Guideline

UR - http://www.scopus.com/inward/record.url?scp=85072529654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072529654&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2019.08.014

DO - 10.1016/j.bbmt.2019.08.014

M3 - Review article

C2 - 31446198

AN - SCOPUS:85072529654

SN - 1083-8791

VL - 25

SP - 2113

EP - 2123

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

IS - 11

ER -

Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this